{"id":"NCT03503318","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","briefTitle":"Study to Evaluate TV-46000 as Maintenance Treatment in Adult and Adolescent Participants With Schizophrenia","officialTitle":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-04-27","primaryCompletion":"2020-09-30","completion":"2020-12-03","firstPosted":"2018-04-19","resultsPosted":"2021-12-09","lastUpdate":"2023-03-10"},"enrollment":544,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Schizophrenia"],"interventions":[{"type":"DRUG","name":"TV-46000","otherNames":["Risperidone"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"TV-46000 q1m","type":"EXPERIMENTAL"},{"label":"TV-46000 q2m","type":"EXPERIMENTAL"}],"summary":"The purpose of the study is to evaluate the efficacy, safety, and tolerability of different dose regimens of TV-46000 administered subcutaneously (SC) as compared to placebo during maintenance treatment in adult and adolescent participants with schizophrenia. The study will include male and female participants, 13 to 65 years of age, who have a confirmed diagnosis of schizophrenia, are clinically stable, and are eligible for risperidone treatment","primaryOutcome":{"measure":"Time to Impending Relapse (Number of Participants With Impending Relapse) for Intent-to-treat [ITT] Analysis Set","timeFrame":"From randomization up to 108 weeks","effectByArm":[{"arm":"Placebo","deltaMin":53,"sd":null},{"arm":"TV-46000 q1m","deltaMin":13,"sd":null},{"arm":"TV-46000 q2m","deltaMin":23,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"},{"comp":"OG000 vs OG002","p":"<0.0001"}]},"eligibility":{"minAge":"13 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":10},"locations":{"siteCount":81,"countries":["United States","Bulgaria"]},"refs":{"pmids":["40730715","37924833"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":14,"n":179},"commonTop":["Injection site pain","Injection site nodule","Headache","Weight increased","Insomnia"]}}